Healthcare / Medical - PharmaceuticalsUpdated 2026-05-10 22:07 UTC

LON/0J9P stock hub

LON/0J9P has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/0J9Pis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

14.5B

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/0J9P

In the news

Latest news · LON/0J9P

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E12

P25 12.9P50 16.9P75 23.5

Trailing P/E13.3

P25 15.9P50 22.9P75 35.8

ROE30.8

P25 -54.2P50 2.1P75 13.7

ROIC71.4

P25 -38.1P50 3.3P75 11.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/0J9P market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

223

Groups with data

Currency

USD

Showing 223 of 223 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	UK
Employees	2,844
Employees Change	227%
Employees Change Percent	8.67
Enterprise value	$11.5B
Exchange	London Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Medical - Pharmaceuticals
Isin	US45337C1027
Last refreshed	2026-05-10
Market cap	$14.5B
Price	$98.37
Price currency	USD
Rev Per Employee	1,427,541.23x
Sector	Healthcare
Sic	2836
Symbol	lon/0J9P
Website	https://www.incyte.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	7.5%
EV Earnings	10.64x
EV/EBIT	10.81x
EV/EBITDA	10.1x
EV/FCF	10.5x
EV/Sales	2.93x
FCF yield	7.6%
Forward P/E	11.96x
P/B ratio	3.39x
P/E ratio	13.33x
P/S ratio	3.56x
PE Ratio10 Y	96.2x
PE Ratio3 Y	138.1x
PE Ratio5 Y	95.66x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	27.13%
EBITDA Margin	28.89%
FCF margin	27.06%
Gross margin	52.77%
Gross Profit	$2.1B
Gross Profit Growth	91.9%
Gross Profit Growth Q	20.25%
Gross Profit Growth3 Y	20.72%
Gross Profit Growth5 Y	21.22%
Net Income	$1.1B
Net Income Growth	6,631.44%
Net Income Growth Q	91.74%
Net Income Growth Quarters	4%
Net Income Growth Years	1%
Net Income Growth3 Y	64.04%
Net Income Growth5 Y	24.51%
Pretax Margin	33.09%
Profit Margin	26.71%
Profit Per Employee	$381,256
Profitable Years	5
ROA	13.89
Roa5y	7.33
ROCE	24.86
ROE	30.82
Roe5y	16.25
ROIC	71.39
Roic5y	36.75

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	65.19%
Cagr3y	14.02%
Cagr5y	3.52%
EPS Growth	7,175.4
EPS Growth Q	83.75
EPS Growth Quarters	6
EPS Growth Years	1
EPS Growth3 Y	69.59
EPS Growth5 Y	26.48
FCF Growth	379.3%
FCF Growth Q	36.61%
FCF Growth3 Y	36.07%
FCF Growth5 Y	20.6%
OCF Growth	296.45%
OCF Growth Q	38.82%
OCF Growth10 Y	23.18%
OCF Growth3 Y	32.73%
OCF Growth5 Y	14.67%
Revenue Growth	21.48x
Revenue Growth Q	20.87x
Revenue Growth Quarters	32x
Revenue Growth Years	13x
Revenue Growth3 Y	15.6x
Revenue Growth5 Y	14.68x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.82
Assets	$5.6B
Cash	$3B
Current Assets	$4B
Current Liabilities	$1.1B
Debt	$29.9M
Debt EBITDA	$0.03
Debt Equity	$0.01
Debt FCF	$0.03
Equity	$4.3B
Interest Coverage	622.3
Liabilities	$1.3B
Long Term Assets	$1.5B
Long Term Liabilities	$207.1M
Net Cash	$3B
Net Cash By Market Cap	$20.84
Net Cash Growth	68.1%
Net Debt EBITDA	$-2.57
Net Debt Equity	$-0.71
Net Debt FCF	$-2.74
Tangible Book Value	$4.1B
Tangible Book Value Per Share	$20.38
WACC	8.63

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.68
Inventory Turnover	28.2
Net Working Capital	$-8.5M
Quick ratio	3.4
Working Capital	$3B
Working Capital Turnover	$1.4

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.21%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	65.13%
200-day SMA	93.93
3Y total return	48.26%
50-day SMA	95.54
50-day SMA vs 200-day SMA	50over200
5Y total return	18.87%
All Time High	112.6
All Time High Change	-12.64%
All Time High Date	2026-01-08
All Time Low	50.02
All Time Low Change	96.66%
All Time Low Date	2024-04-30
ATR	4.86
Beta	0.8
Ch YTD	-0.77
High	102
High52	112.6
High52 Date	2026-01-08
High52ch	-12.64%
Low	95.56
Low52	58.42
Low52 Date	2025-05-08
Low52ch	68.4%
Ma50ch	2.96%
Price vs 200-day SMA	4.72%
RSI	59.18
RSI Monthly	64.19
RSI Weekly	55.47
Sharpe ratio	1.53x
Sortino ratio	2.75
Total Return	0.21%
Tr YTD	-0.77
Tr1m	4.43%
Tr1w	2.04%
Tr3m	-8.41%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$1.1B
Operating Income Growth	593.4
Operating Income Growth Q	49.54
Operating Income Growth3 Y	42.51
Operating Income Growth5 Y	22.82
Operating margin	27.13

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	167,567,809%
Net Borrowing	-3,402,037.9
Shares Insiders	0.46%
Shares Institutions	87.64%
Shares Qo Q	1.01%
Shares Yo Y	-0.21%
Short Ratio	7.5

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$907.5M
Average Volume	1,201.35x
Bv Per Share	21.3
CAPEX	$-49.9M
Ch1m	4.43
Ch1w	2.04
Ch1y	65.13
Ch3m	-8.41
Ch3y	48.26
Ch5y	18.87
Ch6m	-6.46
Change	0.87%
Change From Open	2.94
Close	97.52
Days Gap	-2.01
Depreciation Amortization	69,482,847.2
Dollar Volume	381,478.9
Earnings Date	2026-04-28
EBIT	$1.1B
EBITDA	$1.2B
EPS	$5.35
F Score	7
FCF	$1.1B
FCF EV Yield	9.53x
Financing CF	150,353,063
Fiscal Year End	December
Founded	1,991
Goodwill	97,557,362
Graham Number	69.38381
Graham Upside	-29.47
Income Tax	$259.1M
Investing CF	-145,334,403
Is Primary Listing	0
Last Earnings Date	2026-04-28
Last Report Date	2026-03-31
Lynch Fair Value	$181
Lynch Upside	83.91
Ma150	97.93
Ma150ch	0.45%
Ma20	96.83
Ma20ch	1.59%
Net CF	1,150,772,658
Next Earnings Date	2026-07-28
Open	95.56
P FCF Ratio	13.15
P OCF Ratio	12.58
Position In Range	43.63
Ppne	547,816,128.7
Price Date	2026-05-08
Price EBITDA	$12.32
Ptbv Ratio	3.55
Relative Volume	4.21x
Revenue	4,059,927,251x
SBC By Revenue	4.71x
Share Based Comp	191,211,939
Tax By Revenue	6.38x
Tax Rate	19.28%
Tr6m	-6.46%
Volume	3,878
Z Score	7.94

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LON/0J9P pay a dividend?

Capital-return profile for this ticker.

Performance

LON/0J9P stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LON/0J9P?

Insider, institutional, and short-interest positioning.

Institutional ownership

+87.6%

Share of float held by funds and institutions

Insider ownership

+0.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

LON/0J9P momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

59.2

Neutral momentum band

Price vs 200-day MA

+4.7%

50/200-day relationship not available

Beta (5Y)

0.80

Less volatile than the market

Sharpe ratio

1.53

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/0J9P

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0J9P stock rating?

lon/0J9P is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0J9P analysis?

The full report lives at /stocks/lon/0J9P/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0J9P?

The latest report frames lon/0J9P around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0J9P page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.